RMD's connected device expansion and international growth support its prospects, but rising costs, intense competition and margin pressures pose risks.
Allspring Global Investments Holdings LLC lifted its holdings in shares of ResMed Inc. (NYSE: RMD) by 26.0% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 10,972 shares of the medical equipment provider's stock after acquiring an additional 2,267 shares during the period. Allspring Global Investments
NEW YORK, Nov. 9, 2026 /PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of ResMed Inc. (NYSE: RMD) concerning possible breaches of fiduciary duties. If you are a current shareholder of RMD, you can request additional information here: https://zlk.com/cases/resmed-inc-investigation-rmd or contact Joseph E.
ResMed (NYSE: RMD - Get Free Report) and Terumo (OTCMKTS:TRUMY - Get Free Report) are both large-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, institutional ownership and valuation. Institutional and Insider Ownership 55.0% of ResMed shares are
ResMed, whose devices treat sleep apnea, has dropped on unfounded concerns that weight-loss drugs will replace its treatment. The stock is cheap and worth buying at current prices.
I present 10 high-quality dividend growth stocks with strong total return potential, screened for robust fundamentals and attractive valuations as of November 2026. Key criteria include Investment Score ≥70, future return potential ≥12%, consistent 7%+ dividend growth, and payout ratios below 100%. Top picks such as RMD, NTES, and NVDA offer compelling upside, with future return estimates driven by EPS growth, yield, and potential valuation mean reversion.
Although the revenue and EPS for ResMed (RMD) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
ResMed NYSE: RMD reported first-quarter fiscal 2027 revenue of $1.4 billion, up 6% from a year earlier on a reported basis and 7% on a core constant-currency basis, as growth in sleep devices, masks and residential care software offset declines in life-support device sales. Non-GAAP diluted earnings per share rose 14% to $2.91.